Business Wire

Sharjah Ruler Gifts University of Sacred Heart Historical Manuscript

29.5.2025 19:39:00 CEST | Business Wire | Press Release

Share

His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, presented a rare original historical manuscript to the Catholic University of the Sacred Heart in Milan, Italy, in the presence of Her Highness Sheikha Jawaher bint Mohammed Al Qasimi, Wife of His Highness the Ruler of Sharjah, Chairperson of the Supreme Council for Family Affairs (SCFA).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529504564/en/

Sharjah Ruler gifts University of Sacred Heart historical manuscript (Photo: AETOSWire)

The manuscript dates back to August 14, 1624, and includes a papal decree written by Pope Urban VIII and sealed in the Church of Santa Maria Maggiore in Rome. Additionally, His Highness gifted his book "Papal Bull" in both Arabic and English at the university’s premises.

In his speech, His Highness the Ruler of Sharjah expressed his gratitude and appreciation to the Rector and members of the Catholic University of the Sacred Heart in Milan for their warm welcome.

His Highness spoke about the manuscript he gifted to the university, which dates back to August 14, 1624, highlighting that it is a papal decree written by Pope Urban VIII and sealed in the Church of Santa Maria Maggiore. The purpose of the decree was to raise financial assistance for the Portuguese fleet.

His Highness the Ruler of Sharjah discussed the conflict between the Portuguese and the English in Hormuz, stating, "In 1622, the Portuguese were expelled from Hormuz at the entrance to the Arabian Gulf from the Persian coast, where they had occupied it for one hundred and fifteen years, by English and Persian forces. The mission of the Portuguese leaders, along with the priests, was evangelization, whether in Hormuz, Persia, or India."

His Highness added, "After the English expelled the Portuguese from Hormuz in Persia, King Philip of Portugal sought to retake Hormuz. However, the Portuguese government lacked the financial resources to send a military campaign for its recovery. King Philip requested financial support from the clergy, which led Pope Urban VIII to issue a papal decree to collect the necessary funds from the churches."

His Highness the Ruler of Sharjah explained that he translated and studied this decree, tracking the funds collected through the churches, which amounted to two hundred thousand cruzados, a Portuguese gold currency at the time. The goal was to build a fleet and send it to India to retake Hormuz. His Highness noted that the fleet required a special type of large ship capable of crossing oceans, which would take considerable time, along with a sailing journey from Portugal to India that would last several months.

His Highness indicated that King Philip ordered the funds to be sent to India to build a local fleet there, due to the short distance between India and Hormuz. He explained that the details of this fleet and its armament are mentioned in the book "Papal Bull " that he authored, as well as the account of its journey to the battle site in Hormuz against the English and Dutch forces, culminating in the defeat of the Portuguese fleet.

His Highness the Ruler of Sharjah received a commemorative gift from the Rector of the Catholic University of the Sacred Heart, which was an original 3D map of the city of Milan dating back to 1657.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20250529504564/en/

Contacts

Hussain Al Mulla
Hussain.AlMulla@SGMB.ae
00971563980067

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye